
    
      Subjects will receive oral 5-azacitidine and romidepsin, administered as follows: oral
      5-azacitidine from Days 1-14 (Dose cohorts -1 to 5) or Days 1-21 (Dose cohort 6); and
      romidepsin administered intravenously on Days 8 (Dose cohorts 1-4) of a 28 day cycle, and Day
      22 (Dose cohorts 5 and 6) of a 35 day cycle. Cohorts of 3 patients will be enrolled
      sequentially as outlined in the dose escalation scheme. Once the MTD is reached the Phase II
      part of the protocol will be initiated in patients with T-Cell Lymphoma.
    
  